When does Novo Nordisk report earnings and why does it matter for NOV.DE stock?

Novo Nordisk reports earnings on **04 Feb 2026**. The print matters because it will update sales trends for diabetes and obesity, EPS versus **€3.13**, and guidance—each can move NOV.DE stock significantly on XETRA trading.

What are the main valuation metrics to watch for NOV.DE stock?

Key metrics are **PE 15.98**, price/sales **5.26**, price/book **9.77**, and free cash flow per share **€14.11**. These show strong profitability but a rich book value multiple relative to peers.

What price targets should investors consider for NOV.DE stock?

Meyka AI projects a near-term model price of **€51.97** (+3.69%). We list a conservative 12‑month target **€68.00** and a downside guard at **€48.00**. These are model outputs, not guarantees.

How should traders position for post-earnings moves in NOV.DE stock?

Traders should size for volatility, watch liquidity on XETRA and set stops near **€48.00**. Positive EPS or guidance surprises could push price toward **€52.00** intraday, while weak numbers often trigger larger declines.

DE Stocks

Novo Nordisk (NOV.DE XETRA) pre-market: earnings due Feb 4, watch €50.12 support

ByDanny Kontos February 3, 2026

NOV.DE stock opens pre-market on 03 Feb 2026 with €50.12 on the tape and the company set to report earnings on 04 Feb 2026. Investors will focus on diabetes and obesity sales growth and guidance after a 1‑year decline of -37.53% despite a recent 1‑month gain of 11.48%. We flag valuation, EPS, and near-term catalysts ahead of the report and show where analysts and our model see risk and upside.